多西他赛治疗老年晚期非小细胞肺癌的临床观察

Observation of docetaxel in the treatment of elderly patients with non-small cell lung cancer

目的探讨多西他赛治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法34例年龄>70岁的老年晚期NSCLC患者多西他赛60～75mg/m2静脉滴注,第1、8天,连用2周后休息1周。3周为1周期,2周期后评价疗效。结果34例患者中可评价疗效的有32例,其中获得CR2例,PR10例,SD14例,PD6例,总有效率为(CR+PR)37.5%,临床获益率为(CR+PR+SD)81.3%;经治疗后患者的KPS评分由75.6分上升到86.8分,平均提高11.2分(P<0.01);咳嗽、胸痛、气促的LCSS评分较化疗前明显升高(P<0.05)。不良反应轻,可以耐受。结论多西他赛治疗老年晚期NSCLC是安全有效的,并能改善生活质量,患者耐受性好。

Objective To observe the safety and efficacy of docetaxel in treating elderly patients with non - small cell lung cancer. Methods Thirty-four cases of elderly patients who were over 70 years with advanced NSCLC were treated with docetaxel 60 -75mg/m^2 ,iv, at I st and 8th day. Chemotherapy was repeated every 3 weeks. Patients would be evaluated for response after two cycles of treatment. Results In the 32 patients who were evaluated, 2 cases had complete regression（CR） , 10 cases PR,14 cases SD and 6 cases PD. The overall response rate was 37.5%. The clinical beneficial response rate was 81.3%. Mean KPS was increased from 75.6 at baseline to 86.8 （ P 〈 0.01 ）. Lung cancer symptom scale （LCSS） scores of cough, chest pain and dyspena were increased （ P 〈 0.05 ）. The side effects were mild. Conclusion Docetaxel are effective, feasible and well-tolerated,and may improve quality of life monothrapy in elderly patients with advanced NSCLC.